Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34872
Title: Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
Austin Authors: Mackintosh, John A;Keir, Gregory;Troy, Lauren K;Holland, Anne E ;Grainge, Christopher;Chambers, Daniel C;Sandford, Debra;Jo, Helen E;Glaspole, Ian;Wilsher, Margaret;Goh, Nicole S L ;Reynolds, Paul N;Chapman, Sally;Mutsaers, Steven E;de Boer, Sally;Webster, Susanne;Moodley, Yuben;Corte, Tamera J
Affiliation: Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.;Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia.
Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Department of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.
Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.;Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.;University of Adelaide, Adelaide, South Australia, Australia.
Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia.
Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand.
Respiratory and Sleep Medicine
Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.;University of Adelaide, Adelaide, South Australia, Australia.
Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.
Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand.
Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.;Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
;Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia.
Issue Date: Feb-2024
Date: 2024
Publication information: Respirology (Carlton, Vic.) 2024-02; 29(2)
Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34872
DOI: 10.1111/resp.14656
ORCID: 0000-0002-5254-4144
0000-0001-9979-8726
0000-0003-2061-845X
0000-0002-6565-9928
0000-0002-9553-5870
0000-0002-5118-2890
0000-0003-2046-8957
0000-0003-2065-4346
0000-0002-2273-1774
0000-0002-0777-1196
0000-0002-7096-9365
Journal: Respirology (Carlton, Vic.)
PubMed URL: 38211978
ISSN: 1440-1843
Type: Journal Article
Subjects: idiopathic pulmonary fibrosis
interstitial lung disease
progressive pulmonary fibrosis
pulmonary fibrosis
treatment
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Apr 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.